X4 Pharmaceuticals, Inc - XFOR
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 7.3% | 6,889,163 | View |
| May 15, 2026 | SCHEDULE 13G/A | Joseph Edelman | 7.3% | 6,889,163 | View |
| May 15, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 7.3% | 6,889,163 | View |
| Feb 17, 2026 | SCHEDULE 13G | Saturn V Capital Management LP | 7.36% | 6,433,481 | View |
| Feb 17, 2026 | SCHEDULE 13G | Xiaoying Tian | 7.36% | 6,433,481 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bain Capital Life Sciences Fund, L.P. | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bain Capital Life Sciences Fund II, L.P. | 0.07% | 64,190 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BCIP Life Sciences Associates, LP | 0.01% | 7,817 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BCLS II Investco, LP | 0.8% | 758,598 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BCLS I Investco, LP | 0.09% | 89,633 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BCLS II Equity Opportunities, LP | 7.43% | 7,047,216 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 2.1% | 1,827,005 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 2.1% | 1,827,005 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 1.5% | 1,339,509 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 1.5% | 1,339,509 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.2% | 194,535 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.2% | 194,535 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 3.6% | 3,166,514 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 3.9% | 3,411,993 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 3.9% | 3,411,993 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 3.9% | 3,411,993 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Trails Edge Capital Partners, LP | 5.8% | 5,227,222 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Trails Edge Biotechnology Master Fund, LP | 5.8% | 5,227,222 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Ortav Yehudai | 5.8% | 5,227,222 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Nantahala Capital Management, LLC | 2.8% | 2,449,468 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Wilmot B. Harkey | 2.8% | 2,449,468 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Daniel Mack | 2.8% | 2,449,468 | View |
| Feb 12, 2026 | SCHEDULE 13G | Morgan Stanley | 9.4% | 8,196,489 | View |
| Feb 12, 2026 | SCHEDULE 13G | Morgan Stanley Investment Management Inc. | 9.4% | 8,196,455 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | FMR LLC | 9.7% | 8,499,100 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 9.7% | 8,499,100 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.